Related Experiment Video
Updated: Aug 29, 2026
Pentylenetetrazole-Induced Kindling Mouse Model
Published on: June 12, 2018
Pharmacological and biochemical evaluation of triethyltin's anticonvulsant effects
Abstract:
Acute treatment of mice with triethyltin (TET) causes dose dependent anticonvulsant effects as determined by the maximal electroshock (MES) test: grade 1 (minimal) to grade 5 (maximal) seizures. Thirty minutes following 1 or 5 mg/kg TET mice exhibit 20% grade 4 and 80% grade 5 seizures or 90% grade 2 and 10% grade 3 seizures, respectively. These studies were designed to examine the neuropharmacological and neurochemical basis of this anticonvulsant effect. For MES testing, mice were injected with either reserpine, yohimbine, propranolol, haloperidol or metergoline prior to dosing with TET. Only reserpine and yohimbine blocked the previously noted anticonvulsant effects of TET. For chemical seizure testing, bicuculline ad picrotoxin were injected 30 minutes following TET. TET significantly decreased the convulsant effects of these GABAergic blockers. These results are interpreted to mean that TET preferentially interacts with the alpha-adrenergic and GABAergic transmitter systems to produce its anticonvulsant effects. In vitro receptor binding assays revealed no direct agonist activity of TET at either of these two sites. Possible alternative mechanisms are discussed.
Insights
Triethyltin (TET) demonstrates anticonvulsant properties in mice, significantly reducing seizure severity. Its effects are mediated through interactions with alpha-adrenergic and GABAergic systems, not direct receptor binding.
Area of Science:
- Neuropharmacology
- Neurochemistry
- Toxicology
Background:
- Triethyltin (TET) is known to induce neurotoxicity.
- Acute TET administration exhibits dose-dependent anticonvulsant effects in mice.
- The underlying neuropharmacological and neurochemical mechanisms of TET's anticonvulsant activity require elucidation.
Purpose of the Study:
- To investigate the neuropharmacological basis of triethyltin-induced anticonvulsant effects.
- To explore the involvement of specific neurotransmitter systems in mediating TET's protective action against seizures.
- To determine if TET directly interacts with alpha-adrenergic or GABAergic receptors.
Main Methods:
- Maximal electroshock (MES) test in mice to assess anticonvulsant effects.
- Administration of TET at varying doses (1 and 5 mg/kg) followed by seizure grading.
- Pre-treatment with neuropharmacological agents (reserpine, yohimbine, propranolol, haloperidol, metergoline) before TET administration.
- Chemical seizure testing using GABAergic blockers (bicuculline, picrotoxin) after TET treatment.
- In vitro receptor binding assays to evaluate direct receptor interactions.
Main Results:
- TET administration resulted in dose-dependent anticonvulsant effects, reducing seizure severity in the MES test.
- The anticonvulsant effects of TET were blocked by reserpine and yohimbine, suggesting alpha-adrenergic involvement.
- TET significantly attenuated seizures induced by bicuculline and picrotoxin, indicating interaction with the GABAergic system.
- In vitro assays showed no direct agonist activity of TET at alpha-adrenergic or GABAergic receptors.
Conclusions:
- Triethyltin exerts anticonvulsant effects primarily through modulation of alpha-adrenergic and GABAergic neurotransmitter systems.
- The mechanism of action does not involve direct binding to these receptors, suggesting indirect interactions.
- Further research is warranted to explore alternative neurochemical pathways responsible for TET's anticonvulsant properties.
Related Concept Videos
01:20Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
01:30Electroconvulsive Therapy